Visual disturbances are a common side-effect of many antiepileptic drugs. Non-specific retino-and neurotoxic visual abnormalities, that are often reported with over-dosage and prolonged AED use, include diplopia, blurred vision and nystagmus. Some anticonvulsants are associated with specific visual problems that may be related to the mechanistic properties of the drug, and occur even when the drugs are administered within the recommended daily dose. Vigabatrin, a GABA-transaminase inhibitor, has been associated with bilateral concentric visual field loss, electrophysiological changes, central visual function deficits including reduced contrast sensitivity and abnormal colour perception, and morphological alterations of the fundus and retina. Topiramate, a drug that enhances GABAergic transmission, has been associated with cases of acute closed angle glaucoma, while tiagabine, a GABA uptake inhibitor, has been investigated for a potential GABAergic effect on the visual field. Only mild neurotoxic effects have been identified for patients treated with gabapentin, a drug designed as a cyclic analogue of GABA but exhibiting an unknown mechanism while carbamazepine, an inhibitor of voltage-dependent sodium channels, has been linked with abnormal colour perception and reduced contrast sensitivity. The following review outlines the visual disturbances associated with some of the most commonly prescribed anticonvulsants. For each drug, the ocular site of potential damage and the likely mechanism responsible for the adverse visual effects is described.
INTRODUCTION
Epileptologists administer antiepileptic drugs with the combined aim of managing seizures, minimising side-effects and maintaining an acceptable quality of life for the patient. All of the antiepileptic drugs (AEDs) commonly used to control seizures in the UK are associated with some adverse effects; these range from mild effects such as nausea and weight gain, to more serious life-threatening complications including renal, hepatic and cardiovascular changes 1 . The number of marketed AEDs has increased considerably over the last decade, with many of the newer agents eliciting fewer side-effects 2 ; visual disturbances, however, remain a relatively common occurrence (Table 1) .
Visual disruption in patients diagnosed with epilepsy may be attributable to either the disease process 3 , or the anticonvulsant therapy prescribed to control the seizures. While many mild visual disturbances such as diplopia, nystagmus and blurred vision may simply be an early neurotoxic complication of extended treatment or dosage, other, more specific ocular complaints may be related to the unique mechanistic properties of the drug and can occur even when administered at therapeutic levels. Steinhoff et al. 4 recommended the retina as a parallel model to study the mechanistic properties of anticonvulsant therapy on cortical and cerebral function. The retina is ontogenically part of the brain, and studies have shown that epileptogenic mechanisms including GABAergic and glutamatergic neurotransmission and ion-dependent membrane conductance are mediators of retinal signal transmission 4, 5 . The following review will outline the main visual effects GABA is synthesised in the presynaptic nerve terminal from glutamate by the enzyme glutamic acid decarboxylase (GAD). GABA containing vesicles release the neurotransmitter into the synaptic cleft where it diffuses across to bind with GABA receptors on the post-synaptic neuron. Three heterogenous receptors are known to exist in the vertebrate retina and central nervous system; GABA-A, GABA-B and GABA-C subtypes 10 . GABA-A and GABA-C receptors are particularly abundant in the retina 12, 13 where receptor binding triggers the opening of chloride channels which is inhibitory to neuronal firing. GABA-C receptors differ markedly from the other subtypes in two main ways: (1) they are highly sensitive to GABA 14 , thus even at low concentrations the neurotransmitter can initiate a response; and (2) they initiate a sustained response to GABA, rather than a transient response which is true for GABA-A receptors 10 . The inhibitory action of GABA is limited via active reuptake into the presynaptic nerve terminals and surrounding glial cells. To date, four distinct high-affinity GABA transporters (GAT) have been cloned 6 , three of which have been identified in the vertebrate retina 15, 16 .
There are several ways in which anticonvulsant drugs may enhance inhibitory neurotransmission ( Fig. 2) : GABA-mediated increases in chloride conductance may be enhanced; GABA levels may be raised by stimulating the enzyme GAD; the release of GABA may be enhanced; and, the reuptake and degradation of GABA may be inhibited.
AEDs UTILISING GABAergic MECHANISMS Vigabatrin

Visual field loss
Vigabatrin (␥-vinyl GABA) elicits an antiepileptic effect by binding irreversibly to GABA-transaminase 17 , thereby increasing GABA levels and enhancing inhibitory neurotransmission in the brain. Vigabatrin has been targeted largely at the management of partial seizures and infantile spasms and was used until the late 1990s when isolated reports of concentric peripheral visual field loss and visual electrophysiological abnormalities began to emerge. 7 . The mechanisms of action for sodium valproate and felbamate, which are thought to be GABA-influencing, but are less clear, are not included.
Vigabatrin-associated visual field loss has been identified with both kinetic and static perimetry and is unique, characteristically presenting as bilateral concentric nasal constriction with temporal and central sparing 18 , an example of which is shown in Fig. 3 . This distinct visual field abnormality is unusual as binasal visual field loss attributable to other causes is rare; optic neuritis, including the toxic tobacco form, can occasionally yield bilateral visual defects 19 , however, these are readily distinguishable from vigabatrinrelated defects as they include cecocentral scotoma. Recent estimates of vigabatrin-associated visual field loss suggest that approximately 30% of epilepsy patients receiving the anticonvulsant at normal therapeutic levels present with abnormalities 18, 20, 21 , although this figure varies with some authors reporting higher prevalences [22] [23] [24] [25] , and others reporting slightly lower prevalences [26] [27] [28] . Gender differences have been revealed in some studies, suggesting that men receiving vigabatrin are more susceptible to visual field constriction than women 18, 27, 29 , however, this is not a consistent finding 21 . The vast majority of vigabatrinassociated visual field constriction cases are asymptomatic 18, 20, 21, 23 . In clinical ophthalmology, patients with visual field defects often remain asymptomatic until the defect impinges on, or close to, fixation; this is particularly likely in the case of binasal defects where the preserved temporal visual field in each eye enables patients to retain good mobility.
Longitudinal investigations of vigabatrin-associated visual field loss have reported the defects to be permanent [30] [31] [32] , persisting even after patients are withdrawn from the drug 27, 33 . The majority of patients are withdrawn from vigabatrin with the advent of visual field loss, however in a 1-year follow-up of patients with definite visual defects who continued to take vigabatrin, no evidence of progressive loss was found on repeated testing 34 . A few isolated cases of visual field improvement following cessation of vigabatrin have been described in children 24, 35 , however, these findings are rare and may well be attributable to learning effects.
Several studies have questioned whether visual field damage correlates with vigabatrin cumulative dose with many reporting a significant relationship 26, 28, 31, 32, [36] [37] [38] , and others failing to demonstrate any correlation 21, 27, 39 . The significance of drug interactions arising from adjunctive therapy has also been addressed. In a summary of a series of vigabatrinrelated investigations Sorri 21 reported no significant difference between the visual field defects of epilepsy patients receiving vigabatrin as monotherapy compared to those receiving it as add-on therapy. However, a study that compared two groups of epilepsy patients treated with vigabatrin and additional therapy of carbamazepine or sodium valproate, identified more severe visual field constriction in the latter group 40 . Sodium valproate influences the GABAergic system and it is possible that the combined effect of two anticonvulsants that influence GABA may be more detrimental to vision than vigabatrin in combination with a none GABAergic acting AED such as carbamazepine.
The reason why only some vigabatrin-treated individuals present with visual field disruption while others remain unaffected is unclear. Hisama et al. 41 suggested that GABA toxicity, or the effect of a metabolite in combination with a predisposing genotype, may be responsible. Thus far, a genetic mutation has not been identified, however a common polymorphism has been cloned which may be suggestive of genetic involvement 41 . An alternate explanation may be offered by altered ocular haemodynamics; decreased retinal and pulsatile ocular blood flow has been described in patients with epilepsy compared to normal healthy volunteers 42, 43 . This finding appears to be further exacerbated in vigabatrin-treated epilepsy patients compared with those treated with other AEDs 42 and it is conceivable that pre-existing ischaemia or a GABA-mediated vascular effect may be contributory to visual disruption 44 .
Colour perception
The short-wavelength (blue) sensitive cones are highly sensitive to acquired colour deficiencies and disruption to these cells can produce short-wavelength (tritan) defects. Toxic injury to the medium-wavelength (green) sensitive cones and long-wavelength (red) sensitive cones is less common, however, damage to these pathways can result in medium-wavelength (deutan) or long-wavelength (protan) defects, respectively. Numerous investigational methods exist for the measurement of colour perception that vary substantially in their depth of exploration. While Ishihara and other standard psuedoisochromatic plates yield relatively simple interpretations of colour vision, the more comprehensive Farnsworth-Munsell (FM) 100-hue test provides a detailed assessment of chromatic function at the fovea. In addition to enabling the separation of individuals into classes of superior, average and low colour discrimination, the FM 100-hue test also facilitates the measurement of zones, or axes, of colour confusion in colour defective patients.
Abnormal colour perception has been demonstrated with Ishihara plates, other standard pseudoisochromatic plates, and the FM 100-hue in some patients treated with vigabatrin [45] [46] [47] . Nousiainen et al. 47 reported acquired colour vision disturbances in epilepsy patients treated with vigabatrin-monotherapy that predominated in the tritanoptic axis and were associated with the temporal extent of visual field loss. A later study, which investigated the effect of a single dose of vigabatrin on normal healthy volunteers using colour visual evoked potential tests together with colour perimetry, described a selective tritanoptic visual impairment consistent with GABAergic inhibition at the retinal level 48 . This important study of normal healthy subjects confirms the existence of vigabatrinmediated colour disturbances that are entirely druginduced and not related to the epilepsy disease process; however, whether the effect was short-lived or ongoing was not reported 48 .
Steinhoff et al. 4 employed a battery of clinical and psychophysical tests to assess visual perception in normal healthy volunteers who had received a single AED dose. The results for vigabatrin were somewhat conflicting: no observable change in the D15 colour vision test was noted, however, increased post-adaptation, increment and transient tritanopia thresholds did occur consistent with augmentation of GABA properties. The authors concluded that the observed changes were a function of neurophysiological alterations related to the specific mechanistic effect of vigabatrin, and not simply a neurotoxic effect. In a related study, the same battery of tests was applied to a group of epilepsy patients chronically treated with a mixture of vigabatrin and carbamazepine 49 ; similar findings were reported, however, the existence of similar changes for other non-GABAergic acting drugs led to difficulty distinguishing between mechanistic and general neurotoxic effects.
In a separate investigation of colour discrimination using the FM 100-hue test in epilepsy patients who had undergone add-on treatment with vigabatrin, 33% of patients exhibited below average colour discrimination and in each case the zone of colour confusion was unresolved 39 . This finding suggested a diffuse, or generalised, colour perception deficit consistent with toxic damage affecting all chromatic pathways equally, and may have been the product of complex drug interactions.
Contrast sensitivity
Contrast sensitivity, the ability of the eye to detect objects of varying spatial frequencies and thus contrast, is a useful measure of foveal function. Nousiainen et al. 50 measured contrast and glare sensitivity in a vigabatrin monotherapy-treated epilepsy group and reported impaired contrast function in patients with concentric white-white visual field loss. Surveys of children treated with vigabatrin have shown that up to half present with subnormal visual acuity and reduced contrast sensitivity where abnormal electroretinogram (ERG) responses co-exist 51, 52 . When the CSV-1000 was employed to assess spatial contrast sensitivity in a group of epilepsy patients who had received vigabatrin polytherapy, abnormal contrast sensitivity was apparent in 66% of patients tested; in each case the defects were most predominant at higher spatial frequencies 39 .
Central visual field loss
While there is extensive evidence of visual field loss in vigabatrin-treated patients, the existence of colour perception disturbances and contrast sensitivity impairment implies that the area within the central 10 • of the retina is also affected. Anatomically, it follows that a diffuse toxic effect would encompass central as well as peripheral retinal areas. Central white-white visual field defects within the innermost 10 • have not been reported for vigabatrin-treated epilepsy patients, however, it is known that in some optic and retinal neuropathies the use of short-wavelength automated perimetry (SWAP), which preferentially stimulates subpopulations of the parvocellular pathway, enables the detection of subtle defects before conventional white-white perimetry 53 . Furthermore, it follows that an acquired tritanoptic colour deficiency previously observed in vigabatrin-treated patients 47 might be expected to yield abnormal results to SWAP, particularly in the central visual field corresponding to foveal function.
Daneshvar et al. 20 reported SWAP 30-2 defects in eight of nine vigabatrin-treated epilepsy patients, while an investigation of SWAP in the central 10 • of a group of vigabatrin-treated epilepsy patients revealed abnormal results in the majority 39 . It was suggested that the subtle defects preferentially detected by SWAP may have occurred as a result of reduced redundancy: where the relative paucity of the blue cones result in an impaired functional response that is detectable earlier than other pathways.
Morphological changes
Laboratory investigations using animal models have identified intramyelinic oedema following prolonged vigabatrin administration in some species 54, 55 . Human histological and clinical studies, however, have failed to find any direct or indirect evidence of intramyelinic oedema following vigabatrin treatment 56 . Morphological change in the retina has been identified peripherally and centrally in vigabatrin-treated patients. A range of non-specific abnormalities have been observed including narrowing of the retinal arterioles 45 , atrophy and tessellation of the peripheral retina 30 , surface wrinkling retinopathy of the macula 45 , abnormalities of the retinal pigment epithelium, irregularities of the macula reflex, and pallor of the optic nerve 30, 57, 58 . Of the aforementioned abnormalities, the most recurrent ophthalmic sign reported in vigabatrin-treated patients is optic disc pallor.
The results of a pathological report for a 41-year-old male with a history of complex partial seizures who had been treated with vigabatrin and subsequently developed bilateral visual field constriction, further clarified the morphological effect of the drug 59 . The patient exhibited signs of peripheral retinal atrophy together with a loss of retinal ganglion cells and nerve fibres of the optic nerve, chiasm and optic tracts; no evidence of intramyelinic oedema could be found. It was suggested that the retinal ganglion cells represented the primary site for toxic injury; furthermore, it was the opinion of the author that the extent of cellular damage would have meant that the presenting visual field loss was irreversible 59 .
Electrophysiological changes
The early animal findings of vigabatrin-related intramyelinic oedema accompanied by reversible alterations in somatosensory and visual evoked potentials (VEPs), acted as a catalyst for human electrophysiological studies. The majority of investigations revealed no alteration to VEPs in vigabatrin-treated patient groups and only isolated cases of delayed VEPs and reduced amplitudes have been reported 20, 45 . This suggests that vigabatrin-associated toxicity is unlikely to be localised in the visual pathway or cortex. Instead, visual electrophysiological disturbances in patients receiving vigabatrin are supportive of a retinal locus of abnormality with defects being localised to the inner and outer retina, particularly at the level of the Müller cells 60 which are known to be GABAergic. Two main vigabatrin-related visual electrophysiological effects have been proposed:
(1) A transient effect on the electro-oculography (EOG) Arden index (light and dark ratios) suggestive of raised GABA levels that ceases when the drug is withdrawn 61, 62 . It has been suggested that this effect may indicate drug efficacy rather than toxicity 63 .
(2) A progressive effect that results in abnormalities of the ERG and is thought to be associated with a risk of visual field loss. This effect persists after the drug is withdrawn.
The most consistent ERG changes associated with vigabatrin-attributed visual loss include increased latency of the ERG photopic b-wave, decreased amplitude of the b-wave, reduced or absent oscillatory potentials and abnormalities of the cone function (30 Hz) flicker response 18, 23, 25, 45, 61, 62, [64] [65] [66] . Abnormal multifocal ERGs have also been identified in vigabatrin patients with co-existing visual field defects 25, 62, 65 , however, the site of abnormality is not always restricted to the area corresponding to visual field damage. This, together with reports of altered cone responses 25, 45 , suggests that vigabatrin-mediated toxicity is not confined to the peripheral retina, but is widespread encompassing central areas.
The usefulness of visual electrophysiological tests to predict and monitor vigabatrin-associated visual field loss has been considered and is particularly relevant when visual field testing proves difficult, unreliable, or impossible. Hardus et al. 67 questioned the usefulness of electrophysiological investigations for predicting visual field loss when abnormalities of the ERG and EOG were only observed in 57 and 50% of epilepsy patients with vigabatrin-related visual field loss. More recently, however, in a study of 29 vigabatrin-treated epilepsy patients of which 68% were found to have visual field constriction, 90% of field-defective patients had accompanying EOG and ERG changes 38 . Furthermore, of the remaining 32% of patients without demonstrable visual field loss, 64% yielded abnormal electrophysiology results. On the basis of these findings, the authors concluded that visual electrophysiological testing does provide an accurate method for monitoring the direct effect of vigabatrin on the outer retina.
Vigabatrin is particularly useful in the treatment of infantile spasms, but perimetry testing in children, particularly those under a developmental age of 9 years, has proved a clinical challenge. Recently, an electrophysiological approach has been applied utilising a field specific VEP consisting of a central and peripheral stimulus that has a sensitivity of 75% and specificity of 87.5% for identifying patients with abnormal visual fields 68 . When the authors compared perimetry results with conventional ERG findings in 12 patients, only the 30 Hz flicker response was helpful in predicting visual field loss and it was suggested that a field specific VEP approach provides a sensitive, specific and well-tolerated technique for confirming vigabatrin-associated visual field loss in children 68 .
Treatment considerations
Kalviainen and Nousiainen 63 recommended that vigabatrin should only be used in combination with other AEDs for patients with resistant epilepsy when all other appropriate combinations have proved unacceptable or intolerable. When treatment with vigabatrin is indicated, visual field testing should be carried out at the start of treatment and at regular time intervals. For children with infantile spasms, the benefits of vigabatrin monotherapy may outweigh the risks. Recently reported findings from an investigation of 91 Finnish children suggested that the prevalence of visual field constriction in children treated with vigabatrin is lower than for adults 28 , however, this needs to be verified.
Topiratmate
Topiramate is a multifaceted drug that utilises several mechanisms to elicit an antiepileptic effect: (1) a state-dependent sodium channel-blocking action 69 ; (2) enhanced GABA-mediated chloride fluxes across the post-synaptic membrane 70 ; (3) positive modulation on the activity of GABA-A receptors 71 ; (4) kainite inhibition to activate the kainite/AMPA subtype of the excitatory amino acid receptor 72 ; (5) carbonic anhydrase inhibition (mild effect). Topiramate is generally administered as adjunctive therapy for children aged 2-16 years and adults with partial onset seizures or primary generalised tonic-clonic seizures 73 .
In a review of topiramate efficacy and tolerability, visual disturbances were among the more common adverse symptoms reported 74 . Topiramate has recently been reported to cause acute myopia and secondary closed angle glaucoma without pupillary block in a small proportion of patients 73, 75 . These findings are more common in females, occur within the normal therapeutic range and usually appear within 10 days of medication onset 76 . The US Food and Drug Administration (2001) announced that following post-marketing data of more than 825 000 patients with topiramate, 22 adults and 1 child have been reported to develop ocular symptoms. The symptoms usually occur within the first month of therapy where patients report an acute onset of decreased visual acuity and/or ocular pain. Ensuing ocular examination has revealed myopia, ocular hyperemia, shallowing of the anterior chamber and elevated intraocular pressure, with or without pupil dilation; choroidal effusions have also been described 73 . It has been suggested that supraciliary effusion and ciliary body swelling may displace the lens and iris anteriorly, secondarily resulting in angle closure glaucoma. While the anticonvulsant properties of topiramate are clear, the reason why a minority of patients present with severe visual side-effects remains to be determined although topiramate has been detected in the vitreous 77 .
Steinhoff et al. 49 investigated the effect of combined carbamazepine and topiramate therapy on the visual perception of epilepsy patients compared to controls and reported impaired colour perception with the D15 test, critical flicker fusion, post-adaptation thresholds and transient tritanopia. The authors postulated that the changes were mainly the result of non-specific retino-or neurotoxic effects, and were not mechanistic.
Tiagabine
Tiagabine, is a new generation drug that acts as a selective and specific inhibitor of both neuronal and glial presynaptic GABA reuptake. As is the case with most AEDs, blurring of vision and nystagmus, which are often associated with over-dosage and neurotoxicity, were amongst the side-effects reported in tiagabine clinical trials 78, 79 . In a review of 42 epilepsy patients who took tiagabine for longer than 6 months in two long-term studies, 39% reported diplopia, difficulty with focusing, and blurring 79 .
Although vigabatrin has been identified in the rat retina, the same experiment did not reveal an accumulation of tiagabine 80 . However, in view of tiagabine's GABAergic action, some investigators have queried whether the drug is associated with visual field loss. In a review of 2531 tiagabine clinical trials records, eight patients tested by confrontation exhibited visual field disruption 81 . Previous brain lesions accounted for the visual field loss in two of the patients, and of the remaining six, the abnormality either resolved naturally or with AED intervention. This study provided reassurance that tiagabine is a visually safe drug, but was limited by the insensitive method used for visual field testing. In an abstract published the following year, 6 out of 12 patients treated with tiagabine were diagnosed with visual field defects that were reportedly similar to those observed for vigabatrin 82 . This publication raised concern and was subsequently a subject of discussion 83 . A number of studies have now concluded that tiagabine does not cause visual field or sensory defects [84] [85] [86] [87] and it is possible that previously described abnormalities may have been the result of methodological differences 88 . Kaufman et al. 89 described a single case of reversible asymptomatic visual field loss in a psychiatric patient with bipolar disorder treated with tiagabine. It is likely, however, that this complicated case represents an isolated incident with too many confounding variables.
Acquired colour vision defects have been described in 50% of patients treated with tiagabine, a number not dissimilar to that seen with some other AEDs 86 . Abnormal contrast sensitivity measures have not been reported 86 . Finally, although a review of the literature has not revealed any evidence for abnormal visual electrophysiological responses in humans treated with tiagabine, animal studies using nipecotic acid, of which tiagabine is an analogue, have reported influences on the photoptic ERG and horizontal cells 90, 91 .
Sodium valproate
The antiepileptic mechanism of action elicited by valproate is unclear, but may form the sum of several convergent mechanisms including enhanced GABAergic transmission 92 and blocked voltage-dependent sodium channels 93 . Overall, reports of abnormal visual function with patients treated with sodium valproate are scarce. In a study that employed the FM 100-hue test to investigate colour vision in three groups of epilepsy patients undergoing different AED treatments, increased error scores were observed in sodium valproate-treated patients when compared to normal subjects 94 ; impairment of chromatic and achromatic increment discrimination and increased post-adaptation thresholds where also described 94 . Two later studies, which investigated colour perception in patients exposed to sodium valproate, yielded normal results 95, 96 .
Sodium valproate has been reported to suppress VEPs in rats 97, 98 via a GABAergic mechanism; altered VEPs have also been reported in children 99, 100 and adolescents 100 treated with the drug. ERG parameters, however, appear to be unaffected 101 .
Ozkul et al. 101 found no evidence of visual field loss or altered visual acuity in an epilepsy group treated with sodium valproate. An isolated case of a 25-year-old woman who had been treated with sodium valproate and later with carbamazepine, who presented with visual field loss similar to that observed in patients treated with vigabatrin, has been reported 102 . The authors suggested that a genetic predisposition to aspecific inhibition of several aminotransferases may have been responsible for this particular case, and that a genetic basis may also help to explain the visual effects of other AEDs on vision in some individuals.
Felbamate
Felbamate is a new AED that acts on both excitatory and inhibitory brain mechanisms by blocking currents evoked by N-methyl-d-aspartate (NMDA) and facilitating GABAergic responses 103 . Its use is limited by side-effects. In a review of the therapeutic efficacy of felbamate, diplopia was reported as a fairly common central nervous system disturbance 104 . An isolated case of reversible downbeat nystagmus and ataxia has been reported following felbamate intoxication 105 .
Benzodiazepines
Benzodiazepine AEDs (diazepam, clonazepam and clobazam) act at distinct allosteric binding sites on the GABA-A receptor-chloride ionosphore, commonly termed the benzodiazepine receptor 106 , to enhance GABA-mediated increases in chloride conductances by increasing the frequency of channel opening. There is a well-documented affinity between benzodiazepines and the mammalian retina 107, 108 . Clonazepam has been associated with improved acquired nystagmus 109 and has been suggested as a possible treatment for nystagmus-induced oscillopsia 110 . Clonazepam has also been investigated for an effect on VEPs in humans and animal models [111] [112] [113] where, compared to placebo, clonazepam reduced VEP amplitudes in young healthy men 113 .
Stafanous et al. 114 carried out an ophthalmic examination for 30 patients treated with long-term benzodiazepine medication. Nineteen of the patients complained of symptoms of irritation, blurred vision or difficulty with reading, however, on examination reduced visual acuities were only present in two patients with a history of amblyopia. Of the group, 43% had retinal abnormalities, but no retinal functional ERG abnormalities could be attributed to the medication, dose or duration of treatment. In an earlier study, Jaffe et al. 115 presented baseline ERG data for a group of healthy volunteers receiving varying doses of diazepam under dark and light adaptation and concluded that diazepam produces an attenuating effect on the ERG that is more pronounced under conditions of light. The ERG effects, mediated from rods and cones, may be explained by the GABA-potentiating effect of diazepam within the inner nuclear layer of the retina which may increase retinal dopamine and act on the photoreceptors 116 . An investigation of pattern-elicited VEPs revealed parallel amplitude reductions in both humans and rats treated with high doses of diazepam 117 , however, no changes were observed in the pattern-reversal VEPs of healthy humans receiving a single dose of the drug 118 . Reduced EOG potentials have also been identified in humans following a single dose of diazepam 119 which is suggestive of diazepam modulation of the outer retina 120 .
A single case of maculopathy in a patient prescribed diazepam to control anxiety has been reported 120 . Diazepam has also been associated with acute glaucoma 121 and allergic conjunctivitis 122 . Reports of visual field constriction following diazepam are scarce; a single case of severe bilateral visual loss in a patient administering 100 mg of diazepam, which normalised following cessation of the drug was ascribed to a possible GABA-mediated effect on the retina or visual cortex 123 . This individual case was based on just two visual field examinations and the possibility of a learning effect was not discussed. Nystagmusinduced by stimulation of the lateral geniculate-body in the rabbit has been shown to be depressed with diazepam, however, the resulting after-stimulus nystagmus was prolonged; it has consequently been suggested that diazepam may act on central nystagmus through mechanisms mediated by GABA 124 .
Barbiturates
Similar to benzodiazepines, the barbiturate AEDs (primidone and phenobarbitone) enhance GABA-mediated increases in chloride conductances by prolonging the duration of channel opening. More specifically, phenobarbitone exhibits a mechanism of action that augments chloride-channel responses to GABA 125 , reduces synaptic responses to glutamate 125 and blocks voltage-activated calcium 126 . Reports of ocular and visual abnormality in patients treated with barbiturates are sporadic. A single case of induced periodic alternating nystagmus, which was attributed to barbiturate intoxication, was described in a male patient treated with both primidone and phenobarbitone 127 . Nordmann et al. 128, 129 described four cases of tunnel vision in epilepsy patients treated with AEDs; three of the patients had received vigabatrin and one had received a mixture of phenobarbitone and progabide, an agonist of post-synaptic GABA receptors, all of which interact with the GABAergic pathway. The authors hypothesised that the retinal toxicity triggered by chronically increased GABA transmission may occur with GABA-mimetic drugs.
Brinciotti 130 carried out a visual electrophysiological investigation of children with chronic high serum levels of phenobarbitone and noted increased P2 latency of the VEP that decreased as the drug serum level reduced. In a later study of visual and auditory function in a group of epileptic children and adolescents who had undergone monotherapy treatment with phenobarbitone, no abnormal manifestations were observed compared to a healthy control group 100 .
AEDs UTILISING NON-GABAergic MECHANISMS Carbamazepine
Carbamazipine is a widely used AED that works by the inhibition of voltage-dependent sodium channels 131 .
Carbamazepine has been reported to affect saccadic eye movements 132 and has been associated with isolated cases of downbeat nystagmus and oscillopsia (illusionary movements of objects) 133 . When prescribed outside of the therapeutic dose, blurred vision, diplopia and nystagmus may occur.
Colour vision disturbances have been reported in epilepsy patients treated with carbamazepine 47, 94 , however, this finding is not universal 49 and studies of the effect of carbamazepine on healthy subjects have yielded conflicting results. Steinhoff et al. 4 delivered a single oral dose of carbamazepine to healthy normal volunteers and did not find any adverse effects on colour perception with the desaturated Lanthony 15 test. In contrast, abnormalities in non-standard colour perimetry that were suggestive of mild disturbances of both the red and blue chromatic pathways have been reported following a single carbamazepine dose in healthy subjects 134 .
Mildly increased error scores, without a clear axis of colour confusion, have been observed with the FM 100-hue test in a group of epilepsy patients treated with carbamazepine monotherapy (n = 14) when compared to a normal subject group 94 . A later study, utilising the same technique, described blue-yellow colour perception deficiencies in carbamazepine-treated epilepsy patients, whereas untreated patients maintained normal colour vision 95 . Steinhoff et al. 49 using a less comprehensive technique for assessing colour perception, did not note any abnormalities for a group of 18 carbamazepine monotherapy-treated epilepsy patients compared to healthy controls.
Sartucci et al. 135 measured contrast sensitivity in 28 patients with uncontrolled epilepsy that had undergone long-term treatment with carbamazepine, and reported loss for all spatial frequencies tested compared to control subjects. Following the addition of vigabatrin, a recovery in contrast sensitivity was reported; this finding is at odds with other studies that have implicated vigabatrin as a contender for impaired contrast sensitivity, and might simply reflect the effect of controlling seizure activity in that patient group. Conversely, no abnormalities in contrast and glare sensitivity were observed in a carbamazepine monotherapy-treated epilepsy group 50 .
A possible retinotoxic effect has been suggested by Nielsen and Syversen 136 who described two patients with reversible retinal pigment epithelial changes following 7 years of carbamazepine therapy. The wide use of this drug in epilepsy and other neurological conditions, together with the absence of similar reported cases suggests that morphological changes due to carbamazepine are extremely rare.
Few reports have identified visual electrophysiological changes in response to carbamazepine, however, a recent study did note increased VEP latencies in both children and adolescents treated with the drug 100 . In an investigation of the visual and ocular outcome of 43 children exposed to prenatal AEDs, the most common of which was carbamazepine, two children presented with severe microphthalamus and one with unilateral optic disc coloboma 137 .
Oxcarbazepine
Oxcarbazepine is a keto-analogue of carbamazepine which is almost immediately converted to a 10-monohydroxy derivative, its main metabolite 103 . The anticonvulsant action of oxcarbazepine is uncertain, however, it may block voltage-sensitive sodium channels, resulting in stabilisation of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and decreased propagation of synaptic impulses. Also, increased potassium conductance and modulation of high-voltage-activated calcium channels may contribute to the anticonvulsant effects. Oxcarbazepine has similar properties to carbamazepine, but has a better tolerability profile.
Some of the most common adverse effects associated with oxcarbazepine are related to the central nervous system and include, amongst others, diplopia 138 . In an open label pilot study of oxcarbazepine of 10 in-patients under evaluation for epilepsy surgery, blurred vision was reported in 10% 139 . The effect of oxcarbazepine and carbamazepine on saccadic and smooth muscle eye movements has been considered 140 : while oxcarbazepine only induced negligible alterations on the eye movement parameters measured, the effects of carbamazepine were more apparent.
Gabapentin
Gabapentin is an amino acid designed as a cyclic GABA analogue to penetrate the blood-brain barrier and act as a GABA agonist. Extensive studies have failed to demonstrate an effect of gabapentin on GABA receptors, GABA uptake or GABA metabolism, yet a GABAergic mechanism has not been ruled out. In a study that assessed the efficacy and tolerability of gabapentin in 599 epilepsy patients, blurred vision and diplopia were among the adverse effects reported 141 . In an earlier study, 13.5% of patients treated with gabapentin reported visual problems 142 . In Steinhoff et al.'s 4 study of visual perception in healthy subjects receiving a single dose of gabapentin, visual acuity and colour visual perception with the D15 test remained unaffected while an improvement in post-adaptation thresholds together with an impairment of critical flicker frequency was described. Although these changes may have been due to non-specific neurotoxic effects, the authors considered this unlikely and suggested a possible antiglutamatergic mechanism. In a follow-up paper, where the same visual tests were applied to a group of epilepsy patients receiving carbamazepine and gabapentin, no significant differences were noted for post-adaption thresholds or critical flicker frequencies compared to control patients 49 .
In a small study of the electrophysiological consequences of gabapentin, three out of seven patients treated exhibited abnormal VEPs and one patient presented with an abnormal pattern ERG 143 . It was suggested that an individual disposition to toxic effects on the transmitter function of the optic nerve might be responsible.
Gabapentin has been shown to elicit a beneficial effect on acquired pendular nystagmus resulting in improved vision due to changes in ocular oscillations 144, 145 . Initially a GABAergic mechanism was hypothesised to explain the improved nystagmus, but a study that compared the effect of a single dose of gabapentin with a one off dose of vigabatrin on acquired nystagmus in multiple sclerosis patients only observed a beneficial effect with gabapentin 146 . The authors suggested an alternate explanation for gabapentin's therapeutic effect involving a possible interaction with cerebral glutamate transmission by inhibition of NMDA receptors.
Phenytoin
Phenytoin is a neuronal sodium channel antagonist 131 used widely for the treatment of both complex partial and generalised epileptic seizures. Phenytoin, in particular, is known to influence the vestibulo-ocular system. In a study that investigated the effect of phenytoin toxicity in healthy volunteers, both horizontal gaze-evoked nystagmus and vertical gaze-evoked nystagmus were identified 147 . More worryingly, isolated cases of total external ophthalmoplegia have also been described in some phenytoin-treated patients, fortunately however, this condition is short-lived and reversible 148 .
In a detailed investigation of the effect of AED therapy on chromatic and achromatic visual perception, patients receiving phenytoin exhibited the most abnormalities, particularly for the FM 100-hue test where elevated error scores, without a clear axis preponderance, were observed 94 . The authors argued that the abnormal findings were unlikely to have been the result of unspecific neurotoxicity. Two further studies have reported colour vision deficiencies in the blue-yellow axis for phenytoin-treated epilepsy patients 95, 96 . It is known that the short-wavelength sensitive pathways are highly susceptible to retinal disease, light and chemicals, decreasing their responsiveness 149 , moreover, depression of this pathway is generally considered as an indicator of retinal dysfunction possibly brought on by the alteration of neurotransmitters via AED therapy 96 .
Ethosuximide
The complete mechanistic action of ethosuximide is unclear. However, it appears to lead to altered neurotransmitter release, control of calcium into nerve terminals and modulation of sodium and chloride conductance. Apart from diplopia, which is a common non-specific visual effect often associated with AEDs, no adverse visual side-effects associated with this drug have been reported in the literature, however, reports of efficacy, adverse reactions and toxicity are limited.
Lamotrigine
Lamotrigine, an AED that is chemically distinct from other anticonvulsants, acts primarily through the inhibition of use-dependent voltage-sensitive sodium channels thus resulting in stabilisation of the presynaptic membrane 150 and inhibiting the release of excitatory neurotransmitters, particularly glutamate 103 . The drug may also inhibit voltage-activated calcium currents, and these combined properties contribute to its wide spectrum of efficacy for epileptic seizures.
Diplopia can occur in cases of acute toxicity resulting from the pharmacological interaction of lamotrigine co-administered with carbamazepine 151, 152 , and when lamotrigine is administered alone at high doses 153 . In a pooled comparison of two clinical databases of children and adolescents with epilepsy, diplopia was reported as an adverse event in 5.4% of patients treated with lamotrigine compared to 0.6% receiving placebo 154 . Moreover, in a multicentre trial of 566 patients treated with add-on lamotrigine therapy, transient diplopia was amongst the adverse effects reported 155 . Rotary nystagmus has been described following overdose with lamotrigine 156 , however, a comparison of carbamazepine and lamotrigine in a group of healthy volunteers revealed altered saccadic eye movements and smooth pursuit eye movements with carbamazepine, but not lamotrigine 157 .
In a visual electrophysiological investigation of the newer AEDs, abnormal pattern ERGs were apparent in 2 out of 13 patients treated with lamotrigine, and of those, an abnormal P100 VEP was apparent in 1 143 . In contrast, a comparison of the electrophysiological effects of phenytoin and lamotrigine revealed no evidence of altered VEPs for either drug 158 .
Wohlrab et al. 159 carried out Goldmann perimetry in a number of children with epilepsy treated with and without vigabatrin and identified a patient with concentric visual field constriction who had been treated only with sodium valproate and lamotrigine. No other reports of visual field constriction have been published. Furthermore, in Steinhoff et al.'s 4 investigation of the effect of anticonvulsant drug therapy on visual perception, no significant effects were identified in healthy volunteers receiving the drug.
Levetiracetam
The precise mechanism by which levetiracetam exerts its antiepileptic effect is unknown: it does not appear to work through any recognised excitatory or inhibitory route 103 . Laboratory studies have shown, however, that levetiracetam reverses the effects of negative allosteric modulators of GABA-gated currents and inhibits high-voltage-activated N-type calcium currents in some cultured neurones 160 . In a review of the European and the USA continuation data for all epilepsy patients included in clinical trials and exposed to levetiracetam between 1991 and 1999, visual abnormalities were not among the adverse effects described that lead to withdrawal 161 .
CONCLUSION
Of the anticonvulsive drugs commonly prescribed in the UK, the large majority are associated with some adverse visual effects. Many of these effects provide an early indication of drug toxicity, over-dosage and long-term use whereas others are thought to be related to the individual mechanistic properties of the drugs and can be observed at therapeutic levels. Drugs that act on the GABAergic pathway, especially vigabatrin, appear to be particularly likely to result in visual symptoms.
